Back to search results

Using Urine Tumor DNA to Guide Bladder Cancer Surveillance

This study is looking at a new way to monitor non-muscle invasive bladder cancer (NMIBC) using a urine test called UroAmp. The goal is to see if this test can help identify patients who might need fewer cystoscopies (a procedure to look inside the bladder). You might be able to join if you are at least 18 years old, have high-risk bladder cancer, and have already received certain treatments like BCG or gemcitabine/docetaxel, with good initial results. We are looking for 56 participants. The main thing we'll be measuring is the number of cystoscopies you have over 24 months.

Study design
This is an interventional study with a planned enrollment of 56 participants. It is not specified if it is randomized or blinded.
What's involved
The primary endpoint is the number of cystoscopies measured from enrollment to 24 months. This suggests regular monitoring over two years.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 24 months after enrollment to measure the number of cystoscopies.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07187063

Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer

Recruiting
NAAges 18+InterventionalDiagnostic
Lahey Clinic
~56 participants
Updated 2025-09-22 on ClinicalTrials.gov
What's tested:UroAmp Test (Convergent Genomics, Inc.)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of cystoscopies
Measured over From enrollment to 24 months

Conditions

Non-muscle Invasive Bladder Cancer (NMIBC)

Explore related trials

Bladder Carcinoma

NCT07187063

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Lahey Hospital and Medical Center

    Burlington, Massachusettsstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Matthew B Clements, MD, MS · PRINCIPAL_INVESTIGATOR · Lahey Hospital & Medical Center

Who to contact

Linda Topjian
[email protected]
7817448420
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

AUA high-risk bladder cancer1
Received induction BCG or gemcitabine/docetaxel
Negative initial post-induction therapy assessment (negative cytology and cystoscopy +/- biopsy)

Exclusion

High-risk NMIBC within 3 years
Prior induction intravesical therapy
Variant histology
Concurrent upper tract disease

What this trial measures

  • Number of cystoscopiesFrom enrollment to 24 months

    The rate of cystoscopies (cystoscopies per month), compared between the De-intensified and the standard surveillance arms, is the primary outcome measure.